Innovent Biologics, Inc. (HKG:1801)
75.15
-0.95 (-1.25%)
Jun 26, 2026, 4:08 PM HKT
Innovent Biologics Employees
Innovent Biologics had 7,502 employees as of December 31, 2025. The number of employees increased by 1,843 or 32.57% compared to the previous year.
Employees
7,502
Change (1Y)
1,843
Growth (1Y)
32.57%
Revenue / Employee
1.93M HKD
Profits / Employee
120.68K HKD
Market Cap
130.63B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| WuXi Biologics | 13,252 |
| Sichuan Kelun-Biotech Biopharmaceutical | 2,045 |
| Akeso | 3,761 |
| Sino Biopharmaceutical | 21,435 |
| BeOne Medicines AG | 12,000 |
| RemeGen | 3,048 |
| Biocytogen Pharmaceuticals (Beijing) | 1,443 |
| 3SBio | 6,109 |
Innovent Biologics News
- 3 days ago - Innovent's Partner Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of IBI324 (OLN324) in DME and Wet AMD; Studies Commencing in Second Half of 2026 - PRNewsWire
- 6 days ago - Innovent Biologics Announces First Patient Dosed in a Phase 3 Clinical Trial of IBI3003(GPRC5D/BCMA/CD3 Tri-specific Antibody) for the Treatment of Multiple Myeloma - PRNewsWire
- 17 days ago - Tata Technologies launches 4th edition of InnoVent in collaboration with Emerson and AWS - Business Upturn
- 17 days ago - Innovent: Advancements in GLP-1 Metabolic Disease Treatments - GuruFocus
- 20 days ago - 2026 ADA | Innovent Presents Multiple Clinical and Preclinical Results of Next-Generation Obesity & Metabolic Pipeline - PRNewsWire
- 24 days ago - World's First CLDN18.2 ADC for Regulatory Review: Innovent Biologics Announces IBI343 (arcotatug tavatecan) Met Primary Endpoint in International Phase 3 Study in Advanced Refractory Gastric Cancer and NDA Accepted by China NMPA - PRNewsWire
- 27 days ago - Innovent Biologics announces results from PoC study of IBI363 - TheFly
- 27 days ago - 2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC - PRNewsWire